secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0000950170-23-003568
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome licenses Sunosi to Pharmanovia for Europe/MENA; $66M upfront, up to $101M milestones
--------------------------------------------------------------------------------

- Axsome receives $66M upfront; eligible for up to $101M in sales-based and other milestones.
- Pharmanovia gets exclusive rights to commercialize and develop Sunosi in Europe and MENA.
- Axsome will earn a mid-twenties royalty percentage on net sales in the territory.
- Pharmanovia assumes responsibility for all local clinical/regulatory activities, including pediatric studies.
- Sunosi is approved in EU for EDS due to narcolepsy or OSA; deal expands access.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023003568/0000950170-23-003568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017023003568/axsm-20230221.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-003568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer